BioNotebook: Dyax, MacroGenics, Vivaldi and Rexahn
This article was originally published in Scrip
Executive Summary
Dyax prices $60m offering; MacroGenics surges in first day of trading; Vivaldi acquires vaccine assets; and Rexahn licenses academic drug delivery platform.
You may also be interested in...
Five-Plus-Five Equals A Focus On Execution At Lilly In 2023
Executives told Scrip the company is ready to move five programs into Phase III and launch five products this year, including an obesity indication for Mounjaro, but one drug has since received a CRL.
Finance Watch: Fundraising Shows Preference For Later-Stage Companies
Recent financings, including the $150m launch of Pathalys and a planned $100m IPO for Mineralys, illustrate the reality of biopharma funding in 2023 – that having near-term clinical trial milestones are key to fundraising this year. Companies with dwindling cash are conserving the funds they have left.
US FDA Rejects Lilly’s Bid For Donanemab Accelerated Approval In Early Alzheimer’s
Lilly plans to seek traditional approval for its amyloid-clearing antibody after the Phase III TRAILBLAZER-ALZ 2 trial reads out in Q2, but it loses important ground in reimbursement negotiations.